2 Beaten-Down Dividend Stocks to Buy and Hold

Motley Fool11-14

In a stock market that continues to move higher, some good values can still be found. CVS Health's diversified business and entrenched position should help it to overcome challenges. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483777188?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F796833%2Fpharmacist-talking-to-patient.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-11-14 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483777188","market":"us","top_or_hot":-1,"title":"2 Beaten-Down Dividend Stocks to Buy and Hold","media":"Motley Fool","content":"<div>\n<p>In a stock market that continues to move higher, some good values can still be found.\n\n\n\n\n\n\n\nCVS Health's diversified business and entrenched position should help it to overcome challenges.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/14/2-beaten-down-dividend-stocks-to-buy-and-hold/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Beaten-Down Dividend Stocks to Buy and Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Beaten-Down Dividend Stocks to Buy and Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/11/14/2-beaten-down-dividend-stocks-to-buy-and-hold/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a stock market that continues to move higher, some good values can still be found.\n\n\n\n\n\n\n\nCVS Health's diversified business and entrenched position should help it to overcome challenges.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/14/2-beaten-down-dividend-stocks-to-buy-and-hold/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://www.fool.com/investing/2024/11/14/2-beaten-down-dividend-stocks-to-buy-and-hold/","article_id":"2483777188","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F796833%2Fpharmacist-talking-to-patient.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483777188","pubTimestamp":1731585600,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"They're down, but they aren't out, at least not in the eyes of patient investors.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","BK4548":"巴美列捷福持仓","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0061474960.USD":"天利环球焦点基金AU Acc","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4585":"ETF&股票定投概念","MA":"万事达","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BMY":"施贵宝","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4559":"巴菲特持仓","SG9999000418.SGD":"Aberdeen Standard Global Technology SGD","BK4588":"碎股","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","SG9999001424.SGD":"United E-Commerce Fund SGD","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC"},"translate_title":"2只值得买入并持有的股息遭受重创的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MA":1,"BMY":0.9},"content_text":"In a stock market that continues to move higher, some good values can still be found.\n\n\n\n\n\n\n\nCVS Health's diversified business and entrenched position should help it to overcome challenges.\n\n\n\n\n\n\n\nBristol Myers lost exclusivity for Revlimid, but it has survived patent cliffs before and it will again. \n\nThere are plenty of good reasons to invest in dividend stocks. Companies that can sustain increasing payouts for a while probably have strong underlying operations. Automatically reinvesting the dividend will help boost returns over long periods. And, as with all equities, purchasing shares of top income stocks on the dip is even better.Here are two brilliant options along those lines: CVS Health (CVS 0.44%) and Bristol Myers Squibb (BMY -1.03%). Find out why, despite the issues they've faced, both of these healthcare dividend stocks are attractive to investors focused on the long game.1. CVS HealthSlow revenue growth, inconsistent net income, and multiple guidance cuts --  that's what CVS Health's shareholders have had to deal with for the better part of two years. The company saw sales from coronavirus-related products drop, while its Medicare Advantage (MA) business racked up unexpectedly high costs.The third quarter wasn't very different; revenue increased by 6.3% year over year to $95.4 billion. Adjusted earnings per share dropped to $1.09 from the $2.21 reported in the prior-year quarter.Dwindling revenue from COVID-19 test kits was predictable, but CVS needs to find a solution to its Medicare Advantage business problem to get back in the good graces of investors. The company is working on that project, and management promised to restructure the business next year in ways that could lead to it losing some 10% of its MA members but also becoming more efficient.The good news is that the company still has key advantages. It offers diversified and complementary services throughout patients' care journeys, from primary care to health insurance and medicines. CVS is in dozens of communities around the U.S., and millions of people have relied on its services for decades. That sort of entrenched position in an industry as trust-focused as healthcare won't disappear quickly. So, provided it can resolve its MA business issues, the company should be fine over the long run.CVS Health is still proving its versatility. Last year, it launched a subsidiary called Cordavis focused on developing generic and biosimilar medicines, a potentially lucrative endeavor considering the massive ecosystem of patients it already serves and the fact that most people in the U.S. believe the price of drugs is unreasonable. There should be demand for precisely the kinds of cheaper options Cordavis will develop. It won't be just those, either; many of CVS Health's services will be in higher demand with an aging population.What about the dividend? The forward yield is currently 4.8%, while the company has raised its payouts by 90% in the past 10 years. It might be facing issues, but CVS Health should remain a reliable dividend payer for a while.2. Bristol Myers SquibbBristol Myers Squibb recently went through a period of declining sales following the loss of exclusivity for Revlimid, a cancer drug that used to be its top-selling medicine. The company has recovered, partly thanks to newer approvals. In the third quarter, revenue increased by 8% year over year to $11.9 billion -- a respectable performance for a pharmaceutical giant. Adjusted EPS decreased by 10% to $1.80, but that was because of expenses related to recent acquisitions, so it's not a cause for concern.While its performance was pretty decent, BMS still faces some uncertainty, which explains why many investors remain skeptical. The drugmaker will encounter patent cliffs for two of its best-selling medicines by the end of the decade: anticoagulant Eliquis and cancer medicine Opdivo. Combined, these two products made up 45% of the top line in the third quarter, so it's a legitimate worry.Still, BMS has proven it can overcome patent cliffs, just as it did with Revlimid. The company's portfolio of new approvals features medicines whose sales will grow at a good pace well into the next decade.Furthermore, BMS will develop new drugs. The company's pipeline features 51 compounds in development across several therapeutic areas and dozens of potential indications. Continuously developing novel drugs is one of the most important things a pharmaceutical company can do to remain successful -- and Bristol Myers Squibb excels at this exercise.Its business should be strong enough to support its dividend program. The forward yield recently topped 4.4%, while its payouts have grown by more than 62% over the past 10 years. Bristol Myers Squibb remains a solid income stock.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483777188"}